Cover Image
市場調查報告書

在PharmaPoint:神經性病變疼痛--歐洲主要5個國家的醫藥品預測與市場分析

PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 301144
出版日期 內容資訊 英文 238 Pages
訂單完成後即時交付
價格
Back to Top
在PharmaPoint:神經性病變疼痛--歐洲主要5個國家的醫藥品預測與市場分析 PharmaPoint: Neuropathic Pain - 5EU Drug Forecast and Market Analysis to 2022
出版日期: 2014年04月30日 內容資訊: 英文 238 Pages
簡介

神經性病變痛(NP)是感覺運動系統的障礙,和傷害性疼痛(外傷、傷害、發炎造成的疼痛)儼然不同。神經性病變疼痛與傷害性疼痛主要差別在於神經性病變疼痛並沒有持續性刺激傷害受體。尤其是糖尿病神經痛(PDN)、帶狀疱疹後神經痛、三叉神經痛等三個主要症狀。目前所使用的藥劑主要層級有抗驚厥劑、抗憂鬱劑、鴉片類藥物及局部治療等。但儘管有各種治療藥,仍僅有50%的患者顯示有療效,同時還會產生各種副作用,造成耐受性降低。法國今後由於具有最先進運作機制的新(CNV-2197944及CNV-1014802)即將上市,一般預測將獲得大幅市佔率。此外德國與全球各國相同,將繼續主導PDN治療藥領域的市場成長。另一方面,義大利及西班牙由於新藥上市較遲,推動市場的領域將與其他國家有不同的傾向,還有令人意外的是,英國在上述三個領域的結構與美國及其他歐洲國家都截然不同。

本報告提供歐洲主要5個國家(法國·德國·義大利·西班牙·英國)的神經病變性止痛法相關的最新研究·開發情形及市場未來展望分析,彙整疾病概要和治療方法,市場機會及未滿足需求,市場規模趨勢(今後10年份),已上市/臨床實驗中主要的治療藥簡介(功效·安全性·市場競爭力),各國市場的現狀與今後的方向性等資訊,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 神經性病變疼痛臨床症狀:症狀
    • 糖尿病神經痛(PDN)
    • 帶狀皰疹後神經痛(PHN)
    • 三叉神經痛(TN)
  • 病因·病理
    • 病因
    • 病理生理學

第4章 疾病的管理

  • 診斷·治療概要
    • 診斷
    • 治療的概要與指南
  • 法國
    • 診斷·介紹
    • 藥物治療
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭企業的評估

  • 概要
  • 三環抗憂鬱藥物
    • 概要
    • 功效
    • 安全性
  • 鈣離子通道α-2-δ配體(抗痙攣藥)
    • Lyrica
  • 鈉離子通道阻斷抗痙攣藥(TN)
  • 正腎上腺素再吸收抑制劑(抗憂鬱劑)
    • Cymbalta
  • Opioids(類鴉片物質)
    • Nucynta ER/Palexia SR
  • 局部療法
    • Lidoderm/Versatis
    • Qutenza

第6章 未滿足需求與市場機會

  • 概要
  • 醫生的知識/認知度
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 診斷上的課題
  • 低治療率與給藥量少
  • 對藥理學性治療的功效·安全性方面的不滿
  • 高齡患者:藥物的耐受性
  • 合理的/個人化醫療

第7章 開發平台評估

  • 概要
  • 臨床實驗中的有潛力的藥劑
    • Eslicarbazepine Acetate
    • Topical Clonidine Gel
    • Cebranopadol
    • DS-5565
    • CNV-2197944
    • CNV-1014802
    • Eladur(bupibakain·貼片)

第8章 市場未來展望

  • 市場促進·阻礙因素:全世界的課題
    • 推動因素:老年人口的增加
    • 推動因素:第二型糖尿病患病人數的增加擴大了PDN市場
    • 推動因素:新藥的認證
    • 阻礙因素:學名藥支配市場
    • 阻礙因素:選擇臨床實驗最適當的病理學標的之困難
    • 阻礙因素:三叉神經痛治療體制的落後
    • 阻礙因素:與侵入性治療方法的競爭
  • 法國市場
    • 預測
    • 近幾年的主要趨勢
    • 市場促進·阻礙因素
  • 德國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場

第9章 附錄

圖表一覽

目錄
Product Code: GDHC240CFR

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.

The French market will also see the entry of several pipeline drugs with novel, first-in-class mechanisms of action, such as CNV-2197944 (PDN and PHN) and CNV-1014802 (TN), which will add patient share. As is the case in the global market, the overall NP market in Germany will show growth over the forecast period that will be driven predominantly by growth in the PDN segment of the market. Due to the delayed launch of Versatis in Italy, the dominant NP drug classes in the Italian NP market in terms of market share are slightly different compared with the US and the rest of the EU. Similar to Italy, the overall NP market in Spain will show growth over the forecast period that will be driven predominantly by the PDN and PHN segments. Surprisingly, in the UK, the order of the three leading NP products is very different compared with the US and the rest of the EU.

Scope

  • Overview of Neuropathic Pain including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Neuropathic Pain market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Neuropathic Pain.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Clinical Manifestations of Neuropathic Pain - Signs and Symptoms
    • 3.1.1. Painful Diabetic Neuropathy
    • 3.1.2. Postherpetic Neuralgia
    • 3.1.3. Trigeminal Neuralgia
  • 3.2. Etiology and Pathophysiology
    • 3.2.1. Etiology
    • 3.2.2. Pathophysiology

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Overview and Guidelines
  • 4.2. France
    • 4.2.1. Diagnosis and Referral
    • 4.2.2. Drug Treatment
  • 4.3. Germany
    • 4.3.1. Diagnosis and Referral
    • 4.3.2. Drug Treatment
  • 4.4. Italy
    • 4.4.1. Diagnosis and Referral
    • 4.4.2. Drug Treatment
  • 4.5. Spain
    • 4.5.1. Diagnosis and Referral
    • 4.5.2. Drug Treatment
  • 4.6. UK
    • 4.6.1. Diagnosis and Referral
    • 4.6.2. Drug Treatment

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Tricyclic Antidepressants
    • 5.2.1. Overview
    • 5.2.2. Efficacy
    • 5.2.3. Safety
  • 5.3. Calcium Channel Alpha-2-Delta Ligands (Anticonvulsants)
    • 5.3.1. Overview
    • 5.3.2. Efficacy
    • 5.3.3. Safety
    • 5.3.4. Lyrica
  • 5.4. Sodium Channel-Blocking Anticonvulsants (TN)
    • 5.4.1. Overview
    • 5.4.2. Efficacy
    • 5.4.3. Safety
  • 5.5. Serotonin-Norepinephrine Reuptake Inhibitors (Antidepressants)
    • 5.5.1. Overview
    • 5.5.2. Efficacy
    • 5.5.3. Safety
    • 5.5.4. Cymbalta
  • 5.6. Opioids
    • 5.6.1. Overview
    • 5.6.2. Efficacy
    • 5.6.3. Safety
    • 5.6.4. Nucynta ER/Palexia SR
  • 5.7. Topical Therapies
    • 5.7.1. Overview
    • 5.7.2. Efficacy
    • 5.7.3. Safety
    • 5.7.4. Lidoderm/Versatis
    • 5.7.5. Qutenza

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. Physician Knowledge or Awareness
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Diagnostic Challenges
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Low Treatment Rate and Underdosing of Medications
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Unsatisfactory Efficacy and Safety Profiles of Pharmacological Treatments
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Elderly Patient Population - Drug Tolerability
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Rational or Personalized Therapies
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Eslicarbazepine Acetate
    • 7.2.2. Topical Clonidine Gel
    • 7.2.3. Cebranopadol
    • 7.2.4. DS-5565
    • 7.2.5. CNV-2197944
    • 7.2.6. CNV-1014802
    • 7.2.7. Eladur (bupivacaine patch)

8. Market Outlook

  • 8.1. Drivers and Barriers - Global Issues
    • 8.1.1. Driver: Aging Population in the 7MM
    • 8.1.2. Driver: Increase in Prevalence and Diagnosis of Type 2 Diabetes Will Grow the PDN Market
    • 8.1.3. Driver: Approval of New NP Drugs
    • 8.1.4. Barrier: NP Market Dominated by Generics
    • 8.1.5. Barrier: Challenges Selecting the Most Relevant Pathophysiological Targets for Drug Development
    • 8.1.6. Barrier: Underserved Trigeminal Neuralgia Indication
    • 8.1.7. Barrier: Competition from Interventional Therapies
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers
  • 8.3. Germany
    • 8.3.1. Forecast
    • 8.3.2. Key Events
    • 8.3.3. Drivers and Barriers
  • 8.4. Italy
    • 8.4.1. Forecast
    • 8.4.2. Key Events
    • 8.4.3. Drivers and Barriers
  • 8.5. Spain
    • 8.5.1. Forecast
    • 8.5.2. Key Events
    • 8.5.3. Drivers and Barriers
  • 8.6. United Kingdom
    • 8.6.1. Forecast
    • 8.6.2. Key Events
    • 8.6.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed PDN, PHN, and TN Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included In Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. About the Authors
    • 9.6.1. Author
    • 9.6.2. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification of NP Syndromes Based on the Site of Somatosensory Damage
  • Table 2: Signs and Symptoms of NP
  • Table 3: Screening Tools for NP
  • Table 4: NP-Related Signs and Symptoms
  • Table 5: Treatment Guidelines for NP
  • Table 6: Recommended Drug Therapies for NP Conditions by Line of Therapy
  • Table 7: Most Prescribed Drugs for NP by Indication and Line of Therapy in the Global Markets, 2012
  • Table 8: France - NP Diagnosis and Referral Metrics
  • Table 9: France - NP Treatment Metrics
  • Table 10: Germany - NP Diagnosis and Referral Metrics
  • Table 11: Germany - NP Treatment Metrics
  • Table 12: Italy - NP Diagnosis and Referral Metrics
  • Table 13: Italy - NP Treatment Metrics
  • Table 14: Spain - NP Diagnosis and Referral Metrics
  • Table 15: Spain - NP Treatment Metrics
  • Table 16: UK - NP Diagnosis and Referral Metrics
  • Table 17: UK - NP Treatment Metrics
  • Table 18: NNT and NNH for Classes of Oral Drugs used in NP Treatment, 2013
  • Table 19: Select Products Used for NP Treatment, 2013
  • Table 20: Product Profile - Lyrica
  • Table 21: Lyrica SWOT Analysis, 2013
  • Table 22: Product Profile - Cymbalta
  • Table 23: Cymbalta SWOT Analysis, 2013
  • Table 24: Product Profile - Nucynta ER/Palexia SR
  • Table 25: Nucynta ER/Palexia SR SWOT Analysis, 2013
  • Table 26: Product Profile - Lidoderm/Versatis
  • Table 27: Lidoderm/Versatis SWOT Analysis, 2013
  • Table 28: Product Profile - Qutenza
  • Table 29: Qutenza SWOT Analysis, 2013
  • Table 30: Unmet Need and Opportunity in NP
  • Table 31: NP - Promising Drugs in Clinical Development
  • Table 32: Comparison of Drugs in Development for NP, 2014
  • Table 33: Product Profile - Eslicarbazepine Acetate
  • Table 34: Phase II: Efficacy of Eslicarbazepine Acetate in PHN
  • Table 35: Phase II: Efficacy of Eslicarbazepine Acetate in PDN
  • Table 36: Eslicarbazepine Acetate SWOT Analysis, 2013
  • Table 37: Product Profile - Topical Clonidine Gel
  • Table 38: Topical Clonidine Gel SWOT Analysis, 2013
  • Table 39: Product Profile - Cebranopadol
  • Table 40: Cebranopadol SWOT Analysis, 2013
  • Table 41: Product Profile - DS-5565
  • Table 42: DS-5565 SWOT Analysis, 2013
  • Table 43: Product Profile - CNV-2197944
  • Table 44: CNV-2197944 SWOT Analysis, 2013
  • Table 45: Product Profile - CNV1014802
  • Table 46: CNV-1014802 SWOT Analysis, 2013
  • Table 47: Product Profile - Eladur
  • Table 48: Eladur SWOT Analysis, 2013
  • Table 49: NP Market - Drivers and Barriers, 2012-2022
  • Table 50: Sales Forecasts ($) for NP in France, 2012-2022
  • Table 51: Sales Forecasts ($) for PDN in France, 2012-2022
  • Table 52: Sales Forecasts ($) for PHN in France, 2012-2022
  • Table 53: Sales Forecasts ($) for TN in France, 2012-2022
  • Table 54: Key Events Impacting Sales for NP in France, 2012-2022
  • Table 55: NP Market- Drivers and Barriers in France, 2012-2022
  • Table 56: Sales Forecasts ($) for NP in Germany, 2012-2022
  • Table 57: Sales Forecasts ($) for PDN in Germany, 2012-2022
  • Table 58: Sales Forecasts ($) for PHN in Germany, 2012-2022
  • Table 59: Sales Forecasts ($) for TN in Germany, 2012-2022
  • Table 60: Key Events Impacting Sales for NP in Germany, 2012-2022
  • Table 61: NP Market - Drivers and Barriers in Germany, 2012-2022
  • Table 62: Sales Forecasts ($) for NP in Italy, 2012-2022
  • Table 63: Sales Forecasts ($) for PDN in Italy, 2012-2022
  • Table 64: Sales Forecasts ($) for PHN in Italy, 2012-2022
  • Table 65: Sales Forecasts ($) for TN in Italy, 2012-2022
  • Table 66: Key Events Impacting Sales for NP in Italy, 2012-2022
  • Table 67: NP Market- Drivers and Barriers in Italy, 2012-2022
  • Table 68: Sales Forecasts ($) for NP in Spain, 2012-2022
  • Table 69: Sales Forecasts ($) for PDN in Spain, 2012-2022
  • Table 70: Sales Forecasts ($) for PHN in Spain, 2012-2022
  • Table 71: Sales Forecasts ($) for TN in Spain, 2012-2022
  • Table 72: Key Events Impacting Sales for NP in Spain, 2012-2022
  • Table 73: NP Market- Drivers and Barriers in Spain, 2012-2022
  • Table 74: Sales Forecasts ($) for NP in the UK, 2012-2022
  • Table 75: Sales Forecasts ($) for PDN in the UK, 2012-2022
  • Table 76: Sales Forecasts ($) for PHN in the UK, 2012-2022
  • Table 77: Sales Forecasts ($) for TN in the UK, 2012-2022
  • Table 78: Key Events Impacting Sales for NP in the UK, 2012-2022
  • Table 79: NP Market - Drivers and Barriers in the UK, 2012-2022
  • Table 80: Key Launch Dates
  • Table 81: Key Patent/Exclusivity Expiries

List of Figures

  • Figure 1: Nociceptive Versus Neuropathic Pain
  • Figure 2: Etiology and Pathophysiology of NP
  • Figure 3: Pain Pathway - Somatosensory System
  • Figure 4: Pathophysiological Mechanisms of NP at Different Levels of the Nervous System
  • Figure 5: Pathophysiological Targets of NP Drugs
  • Figure 6: NeuSPIG Diagnostic Certainty Algorithm for NP
  • Figure 7: General Treatment Algorithm for NP
  • Figure 8: Competitive Assessment of Mid-to-Late Stage Pipeline Agents in NP, 2012-2022
  • Figure 9: Sales for NP in France by Drug Class, 2012-2022
  • Figure 10: Sales for PDN in France by Drug Class, 2012-2022
  • Figure 11: Sales for PHN in France by Drug Class, 2012-2022
  • Figure 12: Sales for TN in France by Drug Class, 2012-2022
  • Figure 13: Sales for NP in Germany by Drug Class, 2012-2022
  • Figure 14: Sales for PDN in Germany by Drug Class, 2012-2022
  • Figure 15: Sales for PHN in Germany by Drug Class, 2012-2022
  • Figure 16: Sales for TN in Germany by Drug Class, 2012-2022
  • Figure 17: Sales for NP in Italy by Drug Class, 2012-2022
  • Figure 18: Sales for PDN in Italy by Drug Class, 2012-2022
  • Figure 19: Sales for PHN in Italy by Drug Class, 2012-2022
  • Figure 20: Sales for TN in Italy by Drug Class, 2012-2022
  • Figure 21: Sales for NP in Spain by Drug Class, 2012-2022
  • Figure 22: Sales for PDN in Spain by Drug Class, 2012-2022
  • Figure 23: Sales for PHN in Spain by Drug Class, 2012-2022
  • Figure 24: Sales for TN in Spain by Drug Class, 2012-2022
  • Figure 25: Sales for NP in the UK by Drug Class, 2012-2022
  • Figure 26: Sales for PDN in the UK by Drug Class, 2012-2022
  • Figure 27: Sales for PHN in the UK by Drug Class, 2012-2022
  • Figure 28: Sales for TN in the UK by Drug Class, 2012-2022
Back to Top